Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy

Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy

Introduction: Interferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effective and well tolerated, but costly. To gain perspective on the evolving economics of HCV therapy, we compared the cost per cure of a multi-DAA regimen with the pri...

Full description

Bibliographic Details
Main Authors: Jacob A. Langness, David Tabano, Amanda Wieland, Sarah Tise, Lindsay Pratt, Lauren Ayres Harrington, Sonia Lin, Vahram Ghuschcyan, Kavita V. Nair, Gregory T. Everson
Format: Article
Language:English
Published: Elsevier 2017-05-01
Series:Annals of Hepatology
Subjects:
HCV
DAA
SVR
Efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119304090

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119304090

Similar Items